



PHARMACEUTICAL 2023












RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of ANAPTYSBIO INC is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 275%, being 231% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	447,205
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	26,054
Liabilities, Non-Current	0
Other Assets	161,089
Other Compr. Net Income	-4,824
Other Expenses	24
Other Liabilities	0
Other Net Income	-13,546
Other Revenues	10,287
Property and Equipment	2,089
Research and Development	88,798
Selling, General and Administrative Expense	36,643

Output Variable	Value in 1000 USD
Assets	610,383
Liabilities	26,054
Expenses	125,465
Revenues	10,287
Stockholders Equity	584,329
Net Income	-128,724
Comprehensive Net Income	-131,136
Economic Capital Ratio	275%

